Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.
Download your Brochure
Purchase Now

Our industry leading speaker faculty:

To find out what each speaker will be sharing their wisdom on, download your copy of the brochure here.


Karthik Ramakrishnan

Karthik Ramakrishnan

Senior Manager, GHEOR, TEVA

Read more

More information coming soon...

Jonathan Jarow

Jonathan Jarow

Senior Medical Director, FDA

Read more

Dr. Jonathan P. Jarow is currently the senior medical advisor to the Center Director in CDER at FDA. Jonathan previously served as the director of CDER's Office of Medical Policy, chair of the Medical Policy Council, and as deputy director of the Office of Hematology and Oncology Products. He is a Board Certified Urologist and prior to joining the FDA he was in academic medicine for over 20 years. His last academic appointment was Professor of Urology, Pathology, Radiology, and Molecular Biology & Biochemistry at Johns Hopkins University where he worked for over ten years.

Sean McElligott

Sean McElligott

Global Market Access Lead Dermatology, Janssen

Read more

More information coming soon...

Ana Cespedes

Ana Cespedes

SVP & Project Lead, Core competencies for the future of Merck KGaA Healthcare business, Global Marketing & Strategy, Merck KGaA

Read more

“PASSION for the project, day –to-day INNOVATION in all areas, a cohesive TEAM with shared VALUES; these are the best ingredients for professional success”

As the former Head of Global Market Access and Pricing for EMD Serono from 2012-2017, Ana was responsible for developing a global holistic market access strategy, and robust pricing and reimbursement strategies for EMD Serono products. This includes market access plans and guidelines, price analytics, launch pricing and price band setting, as well as acting as the Center of Functional Excellence in Market Access and Pricing.

She started her career in the biotechnology company Serono as Director of Government Affairs in February 2003, managing the development of this area of the company for Spain and Portugal. In June 2007, after the acquisition of Serono by Merck KGaA, Darmstadt, Germany, Ana was named Corporate Affairs Director of Merck S.L., the Spanish subsidiary of Merck KGaA, Darmstadt, Germany, in charge of Communications, Innovation & Continuous Improvement, Government Affairs, Market Access, Regulatory Affairs, & Commercial Compliance, a position she held until September 2012, when she was transferred to the Boston office in Rockland, Massachusetts and appointed Head of Market Access and Pricing. She has also served as Managing Director of the Fundación Salud 2000 (2004-2011), a not-for-profit organization dedicated to the promotion of research.

With 17 years of experience in the healthcare sector, Ana worked as a teacher and researcher at the Universidad Complutense de Madrid (1995-1999), Senior Consultant in HealthCare Strategy at Arthur Andersen (2000-2003), where she worked on numerous projects in the areas of government affairs, market access, strategic positioning and management of healthcare institutions, balanced scorecard implementation, processes redesign and healthcare institutions reorganizations.

PhD in Pharmacy in the areas of genetics and immunology by the UCM (2000), Ana holds a degree in Pharmacy by the UCM (1995), an Executive Master's Degree in Healthcare Institutions Management by Arthur Andersen (2001), and an Executive Degree in General Management by IESE (2009). She graduated as a bachelor and doctorate with high honor. Ana is also professor in the Instituto de Empresa Business School, and founder of the Executive Education Program on Institutional Relations & Market Access (EERIMAS) in Spain.

Riccardo Perfetti

Riccardo Perfetti, MD, PhD

Senior Medical Officer, Vice President Global Medical Affairs, Diabetes Division, Sanofi

Read more

Riccardo Perfetti is the Head of Global Medical Team Diabetes, Vice President Global Medical Affairs, Sanofi. He trained as an endocrinologist at La Sapienza University, Rome, where he also achieved a PhD in molecular endocrinology in a joint training program with the Johns Hopkins University. He spent ten years at the National Institutes of Health (NIH), Bethesda, working as a Senior Research Fellow and Senior Staff Scientist. In the following eight years Dr Perfetti held a number of clinical, teaching and research positions at the Cedars-Sinai Medical Center and at University of California Los Angeles, where he directed the clinical diabetes program and the basic science diabetes research laboratory. Prior to joining Sanofi in 2007, he held several positions at Amgen Inc, including Director, Department of Medical Sciences within the Translation Medicine Department and Global Development Lead with the General Medicine Development Department. In his current role, he is responsible for the clinical evidence generation strategy for approved and development programs. Dr Perfetti has published numerous articles and is a reviewer for several journals.

Dualities of interest: Riccardo Perfetti is an employee of Sanofi.

Peter Juhn

Peter Juhn

Vice President and Global Head of Value-based Partnerships, Amgen

Read more

Dr. Peter Juhn is Vice President and Global Head of Value-based Partnerships at Amgen. He is responsible for implementing partnerships with payers, care delivery organizations and other key healthcare stakeholders that can lead to more clinical improvement opportunities for patients with serious and debilitating illnesses and result in greater overall value for the healthcare system.

Most recently he was Vice President for Integrated Care Services in the Global Diabetes Division at Sanofi, where he was responsible for creating new patient service platforms and their attendant new business models. He led the business planning efforts for the Sanofi joint venture in diabetes with Verily (aka Google Life Sciences).

Gergana Zlateva

Gergana Zlateva

Vice President, Oncology Market Access, Pfizer

Read more

Gergana Zlateva is a VP, Oncology Market Access at Pfizer. Gergana' s team provides both region-specific and global support in the development and implementation of market access, pricing, reimbursement, and health technology assessment strategies for Pfizer's oncology portfolio. Prior to this role, Gergana was the Payer Insights & Access Cluster Lead for North America, and managed a team of colleagues supporting Pfizer's portfolio and its 3 business: GIP, GEP, and VOC.

During her 14 year tenure with Pfizer, Gergana has held various positions of increasing responsibility covering health economics, outcomes research, and pricing and reimbursement activities across several therapy areas and different geographies. Gergana has led multiple cross-functional teams in preparation of pricing and reimbursement negotiations in developed markets and has presented on behalf of PFE to public and private payer organizations in the EU and US.

Prior to joining Pfizer in 2003, Gergana worked for 5 years on public health, civil society, and business development programs with several United Nations agencies.

Gergana holds a PhD in Economics from Fordham University, NY and a BA and MPA from Southern Illinois University, IL. Gergana's CV includes more than 60 peer-reviewed manuscripts, as well as a number of poster and podium presentations.

Debbie Drane

Debbie Drane

SVP Commercial Development, CSL Behring

Read more

Debbie Drane is the SVP of Global Commercial Development at CSL Behring based in the King of Prussia PA office. In this role she is responsible for market development and life cycle management of the current product portfolio and input into early stage development programs. The global commercial development group also provides support services covering a broad range of services including Global Medical Affairs, Heath Economics & Reimbursement, Competitive Intelligence and Commercial Evaluations. Debbie has been with CSL for over thirty years and has held a variety of senior leadership roles in both Australia and the US. Prior to taking up her current role in September 2014 she led the R&D Licensing & Partnership team based in Parkville, Australia. Debbie spent most of her career in R&D in scientific and management roles and holds a Bachelor of Science Degree from University of Melbourne, Parkville, Australia.

Cheng Zhang

Cheng Zhang

Vice President, Life Sciences Business Development, Clover Health

Read more

More information coming soon..

Sandy Leonard

Sandy Leonard

Vice President, Medical Evidence and Observational Research, AstraZeneca

Read more

Sandy Leonard is Vice President, Medical Evidence and Observational Research at AstraZeneca who leads a team of epidemiologists, study delivery professionals, and RWE specialists to deliver impactful medical evidence for the entirety of the AstraZeneca portfolio.

Sandy believes the value of evidence is linked inextricably to the ability to improve the lives of patients. She challenges her to team to deliver scientific insight, seek strategic collaboration and ultimately drive innovative, impactful and efficient medical evidence generation.

Throughout her career, Sandy has developed and implemented key corporate strategies focused on the development and application of evidence throughout the healthcare system, including the evolution of AstraZeneca's evidence generation capabilities, establishing AstraZeneca's RWE strategy and collaboration initiatives, as well as leading AstraZeneca's US government reimbursement team during the implementation of the Medicare drug benefit.

Sandy holds an undergraduate degree in Psychology from the University of Wisconsin – Madison and has a Masters in Public Health, from the University of Tennessee – Knoxville.

Vidya Raman-Tangella

Dr. Vidya Raman-Tangella

SVP, Head Innovation Center of Excellence, UnitedHealthcare

Read more

Dr. Vidya Raman-Tangella serves as the head of the UnitedHealthcare Innovation Center of Excellence. Vidya and her team design, develop and scale breakthrough innovations that help address unmet health needs through the use of cutting-edge concepts and technology, including mobile apps and integrated health and wellness programs.

Vidya is a clinician by training and has more than 20 years of experience in the health care field. Prior to her role at UnitedHealthcare, she held a senior management position at Johnson & Johnson, where she led the design of integrated and tailored health and wellness solutions for employers and health plans. In addition, Vidya helped oversee the company's start-up organization, providing expertise about strategic partnerships and enterprise integration.

Vidya has spoken at numerous health care and technology conferences, including the International Consumer Electronics Show (CES), the Healthcare Businesswomen's Association Conference (HBA), the Employer Healthcare Congress, and the “Unleashing Innovation Summit.”.

Vidya holds a bachelor's of medicine degree and a bachelor's of surgery degree from Osmania University in Hyderabad, India, and she earned a master's of health administration from Cornell University in New York.

John Bardi

John Bardi

Vice President Public Affairs and Digital Medicine Business Development, Otsuka

Read more

John Bardi is Vice President, Government Affairs, & Digital Medicines Business Development at Otsuka America Pharmaceutical, Inc. (OAPI). John oversees strategic business development for Otsuka's digital platform as well as the execution of government policy and advocacy.

Before joining Otsuka, John worked as Vice President, U.S. Managed Markets, and Senior Director, Marketing, for ABILIFY® (aripiprazole) at Bristol-Myers Squibb. Earlier, he worked at GlaxoSmithKline as Vice President, Long Term Care Channel Accounts, and Director of National Accounts, Institutional Sales.

Prior to entering the pharmaceutical industry, John served as Vice President, Clinical and Professional Services, at The Children's Hospital of Philadelphia and assistant administrator at The George Washington University Medical Center in Washington, DC.

John received a B.A. degree from West Chester University and a Master of Health Services Administration degree from The George Washington University.

Ken Carson

Ken Carson

Senior Medical Director, Flatiron Health

Read more

Dr. Ken Carson is a board-certified practicing hematologist and medical oncologist who currently serves as Senior Medical Director at Flatiron Health, where he focuses on real-world evidence generation. Over the course of his career, Dr. Carson's research has focused on the use of large electronic databases to evaluate health care disparities and oncology drug safety.

Dr. Carson also currently practices at Washington University where he specializes in the diagnosis and treatment of patients with hematologic malignancies like lymphomas and leukemia. He joined Washington University School of Medicine's faculty in 2008 and later served as chief of hematology and oncology at the St. Louis Veterans Affairs Medical Center.

Dr. Carson received his medical degree from the University of Southern California, Keck School of Medicine followed by residency training at Duke University, and research and clinical fellowships at Northwestern University. Dr. Carson also received a PhD (with an emphasis in health policy and administration) from the University of Illinois School of Public Health.

David Evans

David Evans

Partner, MME

Read more

With MME, Dave provides critical insights to help clients understand and harness the value of bio-pharmaceutical products.  He has a broad range of experience, both in the industry and consulting.  At Sanofi, Dave was the head of Segment Marketing, responsible for multiple brands across all customer channels.  As head of Pricing and Reimbursement at Daiichi Sankyo, he started the pricing function and built a team responsible for supporting assets in US and EU markets.  Later at Sunovion, he was the Head of Pricing and Access, and the Head of Organized Customer Marketing.  Dave became a Partner at MME in 2014 and works extensively in pricing and net-pricing strategy. 

He’s led the development of pricing strategy for existing brands, launch brands and new product development in the US and EU.  He has experience in lifecycle strategy, ranging from early clinical development to loss of exclusivity (LOE).  Dave has developed payer forecasts, models and decision support systems.  He has deep experience in net-pricing strategy, execution and pricing governance; and has led brand and department level operational planning initiatives.  Dave’s experience enables him to help clients anticipate and navigate internal and external challenges they are likely to face.  Dave holds a Bachelor of Science degree in Business from Brigham Young University.

PRESENTATION:  WHERE THERE’S SMOKE, THERE’S…  ORIGINAL RESEARCH ON THE CURRENT OUTCOMES-BASED CONTRACTING ACTIVITY IN THE US

Attendees will learn the results of original research showing a payer perspective on innovative and Outcomes-Based Contracting (OBC):

  • There is a great deal of press about innovative or OBC contracting, attendees will see the reported real world activity within the US payer market.
  • Understand the payer reported experience with negotiations, and their level of satisfaction.
  • Know the prevalence of different types of innovative contracts, and which kinds payers anticipate growth in over the next three years
  • Understand the health conditions which are prioritized by payers for the future innovative and OBC initiatives
  • Know the factors payers think either drive interest for innovative or OBC initiatives, and which factors create the largest barriers.
Michelle Hoiseth

Michelle Hoiseth

Corporate Vice President, PAREXEL

Read more

Michelle has been working in the drug and medical device development industry for 29 years, through a variety of positions that allowed her to create complete product development plans, design novel regulatory pathways to approval, write both strategic and tactical business development plans, and support product commercialization objectives and life cycle management.  Michelle presently leads the development of PAREXEL's real world data capability, working closely with her colleagues in a multi-disciplinary environment to solve the challenges using real world data in clinical research.  Michelle is committed to leading inclusive, invested, innovative teams to move our industry into the future of clinical product development. 

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription


Edmund Pezalla

Edmund Pezalla

Former Vice President for Pharmaceutical Policy and Strategy, Aetna

Read more

Dr. Pezalla in a leading innovator in payer strategy for pharmaceutical and device manufacturers. He focuses on unlocking the value of new products by developing industry-leading approaches to incorporating payer requirements into development programs, technology assessment plans, and value frameworks. He works with a variety of policy and industry groups on cutting edge coverage policy, innovations in value-based payments, and adaptive regulatory and market entry pathways.

Dr. Pezalla is the former Vice President for Pharmaceutical Policy and Strategy in the Office of the Chief Medical Officer at Aetna. In this position Dr. Pezalla developed and coordinated strategy for pharmaceutical evaluation and coverage across both the medical and pharmacy benefit, created Aetna's framework for innovative contracts, and developed Aetna's public policy positions on drug and device coverage.

Ed Schoonveld

Ed Schoonveld

Principal, Value & Access, ZS

Read more

Ed Schoonveld is a Managing Principal with ZS Associates in New York N.Y. and is the leader of the firm’s Value and Access solution area. In this role, he provides strategic consulting and research solutions to healthcare industry clients. He is considered to be one of the world’s leading experts on global pharmaceutical pricing and market access and has unparalleled experience as head of global market access and pricing functions at Wyeth, Lilly, and BMS, and as a consulting leader at Cambridge/IMS and a number of other organizations. You can learn more about Ed Schoonveld on Twitter and LinkedIn. Ed is the author of The Price of Global Health.

Aaron Mitchell

Aaron Mitchell

Principal, R&D Excellence, ZS

Read more

Aaron Mitchell is a Managing Principal and the global lead for ZS’s R&D excellence practice, based in Zurich, Switzerland. He partners with clients to strengthen the value of their pipelines, optimize the execution of clinical trials, drive the effective use of real-world evidence, and improve medical and scientific engagement. A key area of focus for Aaron is patient-centric drug development, including optimizing clinical trials for patients and leveraging real-world evidence to support product development. Aaron joined ZS in January of 2003. Prior to ZS Aaron was a manager for Deloitte, providing strategic consulting services to clients in a range of industries including financial services consumer products retail and healthcare. He has a Master of Business Administration degree from the Haas School of Business at University of California Berkeley and a Bachelor of Science degree in mechanical engineering from the United States Military Academy at West Point.

Nneka Onwudiwe

Nneka C. Onwudiwe

PRO/PE Regulatory Review Officer, US Government

Read more

Nneka C. Onwudiwe, PhD, PharmD, MBA received her doctorate in Pharmacy from the University of Maryland School of Pharmacy, PhD in Health Services Research with a specialization in Pharmacoeconomics from the University of Maryland School of Pharmacy, and a MBA (Honors) from the University of Baltimore. In addition, she received an honor of Rho Chi in Pharmacy in 2002 and an honor of Beta Gamma Sigma in Business Administration in 2012.

Dr. Onwudiwe is the technical expert and point of contact in the review of patient-reported outcomes (PRO), pharmacoeconomics (PE), and other type of claims in prescription drug promotion for the Division of Advertising and Promotion Review II (DAPR II) within the Office of Prescription Drug Promotion at the Food and Drug Administration (FDA).

Jack Sheehan

Jack Sheehan

RWE Pragmatic Trial Team Lead, Janssen

Read more

Jack Sheehan works as a Real-World Evidence team leader at Janssen Scientific Affairs to effectively and efficiently drive high-priority, prospective, real-world evidence research projects from early stage development through execution and completion in close partnership with other scientific function. He supports the Central Nervous System, Infectious Disease, and Metabolics therapeutic areas.

He has worked across a variety of Medical Affairs functions over 11 years in the pharmaceutical industry. Jack has co-authored 38 papers, ranging from basic science to clinical science to epidemiology and policy. He holds a PhD in Molecular Pharmacology from SUNY Stony Brook and a BS in Pharmacy from Rutgers. He also completed post-doctoral training in Pathophysiology at the University of Pennsylvania and an MBA specialized in economics at New York University.

Deborah Kilpatrick

Deborah Kilpatrick

CEO, Evidation Health

Read more

Deborah is the Chief Executive Officer of Evidation Health. Prior to this role, she served as the Chief Commercial Officer of genomic diagnostics company CardioDx. Earlier in her career, Deborah held multiple leadership roles at Guidant Corporation, including Research Fellow, Director of R&D, and Director of New Ventures in the Vascular Intervention Division. She serves on the Georgia Tech Advisory Board and is a Fellow of the American Institute of Medical and Biological Engineering. Deborah is a co-founder of the MedtechVision Conference, now held annually in Silicon Valley. She holds BS, MS and PhD degrees in mechanical engineering with a bioengineering focus from Georgia Tech.

Margaret McDonald, PhD, MS, MT(ASCP)

Margaret McDonald, PhD

Senior Director, Real World Data and Analytics, Patient & Health Impact, Pfizer

Read more

Margaret McDonald, PhD, MS, MT(ASCP) is a Senior Director in the Real World Data and Analytics (RWDnA) group, part of the Patient and Health Impact function at Pfizer. In her current position, Margaret supports the Internal Medicine, Rare Disease, and Consumer portfolio in the development and delivery of insights using real world data and analytics. Her work includes using rapid cycle query tools for analyses leading to potential studies, consultation on study design and uses of data, presenting at internal and external meetings, and as RWD liaison to Pfizer EU and LATAM country colleagues. Her research focus includes population studies, burden of illness, gaps in healthcare services, and healthcare disparities. Prior to this position, Margaret led the Population Health efforts within Outcomes Research, creating reports used externally by Pfizer colleagues and external organizations.

Margaret has been employed at Pfizer for 16 years. She has a PhD in epidemiology from the University of Massachusetts, and holds a Masters degree in biology from the University of Hartford. Prior to Pfizer, Dr. McDonald was an assistant professor at the Center for Community Health at the University of Southern Mississippi in Hattiesburg; worked at an occupational epidemiology firm; and completed an internship at the Centers for Disease Control and Prevention at the National Center for Health Statistics. Dr. McDonald has also held positions of laboratory management at community hospitals.

Kenneth Beers

Kenneth Beers

Managing Director, Huron Consulting

Read more

Ken serves life sciences clients across a variety of strategic questions, with emphasis on new therapy commercialization, brand and portfolio strategy, and market access. After years of management consulting to life sciences companies and a prior career in scientific research, Ken bridges the commercial, clinical, and regulatory complexities facing the industry. His clients span large pharmaceutical and early-stage biotechnology companies, and include not only manufacturers but also distributors, specialty pharmacies, and service providers. Ken is active in multiple therapeutic areas including oncology, neurology, immunology, infectious disease, cardiology, hematology, respiratory, nephrology, psychiatry, pain management, and genetic rare diseases. Ken has experience in commercializing a wide variety of generic and branded small molecules, biologics, cellular, and gene therapies. Ken's global experience includes the US, EMEA, Asia Pacific, and Latin America.

Andrew Hobbs

Andrew Hobbs

Managing Director, Pope Woodhead

Read more

Andrew is Managing Director of PW. He has more than 25 years' experience in consulting to the pharmaceutical industry, with a particular expertise in value strategy and market access. He has strong links with the University of York and Cambridge University. Prior to joining PW in 2001 he spent six years as a management and technology consultant at Cambridge Consultants, an Arthur D. Little subsidiary

Joseph Dye

Joseph Dye

Head of HEOR, Neurology US, UCB

Read more

Joe is the Head of HEOR for Neurology in the US for UCB, Inc. He was previously a research consultant with Humana’s Comprehensive Health Insights, Inc. leading and working in teams to conduct health economics and outcomes research projects for external pharmaceutical industry clients and internal Humana clients. Prior to his managed care research experience, he also conducted research in the academic setting at Mercer University College of Pharmacy, the hospital setting with Children’s Healthcare of Atlanta, and in the non-profit public health sector with the American Cancer Society. He has served on AMCP’s Program Planning and Development Committee, the JMCP Editorial Advisory Board and as a reviewer for the journal, and the Winter Symposium planning committee for the AMCP Georgia Affiliate. He has authored and coauthored numerous peer-reviewed posters, presentations, and journal manuscripts.

Eduardo Valencia

Eduardo Valencia

Linguist and Data Analytics Manager, MeaningCloud

Read more

Linguist and Data Analytics Manager at MeaningCloud. Writer and international speaker at conferences in the USA, France, Spain, Turkey, United Kingdom Germany, Austria and Italy. The author of the book DATA COACHING (http://eduardovalencia.com/datacoaching).

Reg Waldeck

Reg Waldeck

Market Access Strategy Leader, Bayer

Read more

More information coming soon...

Sean Kennedy

Sean Kennedy

Principal, inVentiv Health

Read more

Sean Kennedy is a Principal with the INC Research / inVentiv Health Real World Evidence team.  He has been working in the Late Stage / Peri-approval space for nearly two decades in academia and industry.  Previously led the Department of Registries and Observational Studies and served a secondment in the UK leading Data Management.  He specializes in design and delivery of bespoke programs to support late stage evidence generation needs.

Michael Mittelman

Michael Mittelman

New Product Development & Capability Manager, Independent Blue Cross

Read more

More information coming soon...

Holly Krasa

Holly Krasa

Senior Director, Health Outcomes, Otsuka

Read more

Holly is Senior Director, Health Outcomes at Otsuka Pharmaceutical Development & Commercialization with over 20 years’ experience in the life sciences industry leading research teams across all phases of product development and commercialization.

Holly currently leads a team focused in health economics, outcomes research and health care implementation research across Otsuka’s portfolio of products focused in mental health and CNS disorders, oncology, kidney disease and digital health/medicine platforms.

Holly holds an undergraduate degree in Biology from the University of Michigan and has a Masters in Neurobiology and Physiology from Northwestern University.

Gavin Birchnall

Gavin Birchnall

Senior Solutions Consultant, ERT

Read more

More information coming soon...

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription